PLANEGG-MARTINSRIED, Germany, December 17 /PRNewswire/ -- The Management Board and the Supervisory Board of the drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC), with its headquarters in Martinsried, Germany, today published their joint statement on the public mandatory offer of Santo Holding (Deutschland) GmbH pursuant to Section 27 (1) of the German Securities Acquisition and Takeover Act (WpÜG).

LONDON, December 17 /PRNewswire/ --

- Upgrades to Mippin Made in Line With Consumer Demand

Mippin, the free mobile web discovery service from Refresh Mobile, which connects you to your favourite web content on the phone, has revealed their users top handsets for accessing the mobile internet in the run up to this Christmas this year. Nokia is the most popular and accounts for over 50% of all Mippin.com access, whilst the iPhone is showing great momentum, already breaking into the US top 10 Mippin handsets. The Motorola RAZR, KRZR are also proving popular.

The Top 5 handsets with Mippin users by country:

OXFORD, England, December 17 /PRNewswire/ --

- New Deal Provides a Further Opportunity for OGeS to Grow its Therapeutic Antibody Pipeline

Oxford Genome Sciences (UK) Ltd "OGeS" announces today that it has entered into a strategic collaboration with Amgen to discover, develop and commercialise novel therapeutic antibodies for the treatment of cancer. This new collaboration will enable OGeS to further strengthen its pipeline of fully human therapeutic antibodies (mAbs) in cancer based on the target discovery capabilities of its unique OGAP(R) database.

LEIDEN, The Netherlands, December 17 /PRNewswire/ --

- Researchers Expect Groundbreaking Results

Today Top Institute Pharma presents a new and highly promising research project. The TI Pharma project is a large-scale study into the brain material of Alzheimer's and Parkinson's patients, who gave permission to the Netherlands Brain Bank for their tissue to be used for scientific research. The analysis is a continuation of highly-promising results from previous studies and focuses on the genes that could be involved in the development of Alzheimer's disease and Parkinson's disease. The study - that must form the basis for potential drugs - is one of the largest to be carried out on an international level.

LONDON, December 14 /PRNewswire/ --

- The Benefits of Anastrozole (Arimidex(R)) Over Tamoxifen at Preventing Breast Cancer Recurrence Improve Over Time - Up to Four Years After Treatment Ends

New data from ATAC(x), one of the world's largest and longest-running studies in postmenopausal women with hormone receptor positive (HR+), early breast cancer, reinforce that anastrozole can help many more women live cancer-free, for longer. The new data show that post-menopausal HR+ women continue to benefit from anastrozole, even up to four years after treatment ends.(1), (2) If breast cancer returns, women are much more likely to die - therefore, preventing breast cancer recurrence is fundamental to saving lives.

SLOUGH, England, December 14 /PRNewswire/ -- Reckitt Benckiser, the manufacturer of Nurofen Plus, has been made aware of the death of a woman earlier this year from acute renal failure who, prior to her death, was taking large quantities of Nurofen Plus (in excess of 48 tablets) daily. This far exceeds the recommended and approved doses (a maximum of six tablets daily).

A Reckitt Benckiser spokesperson comments, "We offer our sincere sympathy to the Docherty family for their tragic loss. However, Reckitt Benckiser would like to reassure consumers that Nurofen Plus, and all other products in the Nurofen range, are safe and effective when taken in accordance with the pack instructions, and used to effectively relieve pain by millions of people every day."